To determine if this observed increase in antigen-specific CD8+ T cell activation could mediate tumour rejection, mice bearing B16-OVA tumours were treated with three injections of MIAP301 or isotype control, and both OT-I cells and OT-II cells were adoptively transferred following antibody treatment. Here, CD8A is linked to neoplasm.